A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer
Saved in:
| Main Authors: | Ji‐Yong Sung, Jae‐Ho Cheong, Kihye Shin, Eui Tae Kim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Clinical and Translational Medicine |
| Online Access: | https://doi.org/10.1002/ctm2.70079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fecal methylated syndecan-2 (SDC2) testing for early screening of colorectal cancerous and precancerous lesions: A real-world retrospective study in China
by: Boyu Qin, et al.
Published: (2025-01-01) -
SDC1 is a critical transmembrane proteoglycan in breast cancer
by: Yingying Mei, et al.
Published: (2025-05-01) -
Significance of Fusobacterium nucleatum Combined with SFRP2 and SDC2 Gene Methylation Detection in Early Screening of Colorectal Cancer
by: ZHONG FANGCHAO, et al.
Published: (2025-06-01) -
Is Syndecan-2 a Key Angiogenic Element?
by: Oriol Noguer, et al.
Published: (2009-01-01) -
Significance of the Syndecan-4-Transglutaminase-2 Interaction
by: Elisabetta Verderio, et al.
Published: (2010-01-01)